Annmarie Surprenant

Title: Annmarie Surprenant: Innovator in Purinergic Receptor Research

Introduction

Annmarie Surprenant is a notable inventor based in Geneva, Switzerland. She has made significant contributions to the field of purinergic receptors, particularly through her innovative research and patents. With a total of 2 patents, her work focuses on methods that could potentially lead to advancements in treating various diseases.

Latest Patents

Surprenant's latest patents include groundbreaking inventions related to the screening of modulators of mammalian P2X7 purinergic receptors. The first patent discusses a purinergic receptor, specifically the P2X receptor, and details a nucleic acid encoding the P2X receptor. This invention also outlines a method for producing P2X recombinantly. Furthermore, it describes a method for screening compounds that can inhibit P2X activity, which may be useful in treating diseases such as arthritic and respiratory disorders, as well as neurodegenerative diseases. The second patent similarly focuses on the P2X7 receptor, detailing its encoding and recombinant production, along with methods for screening compounds to inhibit P2X7 activity for therapeutic applications.

Career Highlights

Annmarie Surprenant is currently associated with Glaxo Group Limited, where she continues her research and development efforts. Her work has positioned her as a key figure in the exploration of purinergic receptors and their implications in medicine.

Collaborations

Surprenant has collaborated with notable colleagues, including Gary N Buell and Eric H Kawashima, contributing to a dynamic research environment that fosters innovation.

Conclusion

Annmarie Surprenant's contributions to the field of purinergic receptors through her patents and research are paving the way for potential new treatments for various diseases. Her work exemplifies the impact of innovative thinking in the medical research community.